시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 직접 쿰즈 검사(DCT) 항체 시장 보고서(2025년)
Direct Coombs Test (DCT) Antibody Global Market Report 2025
상품코드 : 1889362
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,650,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,612,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,575,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

직접 쿰즈 시험(DCT) 항체 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 58억 7,000만 달러에서 2025년에는 65억 5,000만 달러로, CAGR 11.7%로 성장하였습니다. 지난 수년간의 성장은 신생아 용혈성 질환의 유병률 증가, 자가면역성 용혈성 빈혈의 진단 증가, 수혈 치료의 확대, 병원 혈액 은행의 용량 확대, 산전 스크리닝 프로그램 증가로 인한 것으로 예측됩니다.

직접 쿰즈 시험(DCT) 항체 시장 규모는 향후 수년간 급속한 성장이 예상됩니다. 2029년에는 100억 6,000만 달러에 달하고, CAGR은 11.3%를 나타낼 전망입니다. 예측기간 내 성장요인으로는 고령 인구 증가, 종양학과 혈액학 치료 건수 증가, 민간 진단 시험 네트워크의 확대, 유니버설 혈액형 판정과 교차 적합 시험 수요 증가, 용혈성 수혈 반응의 스크리닝 증가 등을 들 수 있습니다. 예측 기간 내 주요 동향으로서는 중합효소 연쇄반응(PCR)에 의한 혈액형 유전자형 판정과 혈청학적 시험 워크플로의 통합, 인공지능을 활용한 품질 관리와 로트 릴리스 분석, 사물인터넷(IoT)을 활용한 콜드체인 모니터링과 추적 가능성, 클라우드 기반 시험실 정보 관리 시스템의 도입, 보존 기간 연장용 동결 건조 기술 등이 있습니다.

맞춤 의료에 대한 수요 증가는 향후 직접 쿰즈 시험(DCT) 항체 시장의 성장을 가속할 것으로 예측됩니다. 맞춤 의료는 치료 성과를 최적화하고 치료를 개선하기 위해 환자의 유전적 요인, 환경 요인, 생활 습관에 따라 치료를 개별화하는 의료 접근법입니다. 유전체 기술의 진보로 유전적 변이의 정밀한 동정과 개인에 맞춘 치료가 가능해지면서 맞춤 의료에 대한 수요가 높아지고 있습니다. 직접 쿰즈 시험(DCT) 항체는 적혈구와 결합한 항체와 보체를 정밀하게 검출함으로써 맞춤 의료를 지원합니다. 이를 통해 면역 매개성 용혈성 질환을 확인할 수 있으며, 임상의는 환자의 특정 면역 프로파일을 기반으로 치료를 조정할 수 있으므로 진단 정확도와 치료 결과를 향상시킬 것으로 기대됩니다. 예를 들어 2024년 2월 미국 비영리 단체인 '맞춤의료연합(PMC)'에 따르면 미국 식품의약국(FDA)이 2023년 26건의 새로운 맞춤 의료를 승인했습니다. 이는 2022년 12건에서 상당히 증가한 수치입니다. 따라서 맞춤 의료에 대한 수요가 증가함에 따라 직접 쿰즈 테스트(DCT) 항체 시장의 성장이 지속되고 있습니다.

직접 쿰즈 시험(DCT) 항체 시장에서 사업을 전개하는 주요 기업은 신뢰성 확보, 시험실 워크플로의 효율화, 수혈 전 시험에서 높은 수준의 유지를 목적으로 하는 겔 기반 면역 측정법 등 첨단 기술 솔루션의 개발에 주력하고 있습니다. 겔 기반 면역 측정법은 항체와 항원이 겔 매트릭스 내에서 상호작용하여 응집 반응과 같은 시각적 검출을 가능하게 하는 시험 기법을 말합니다. 예를 들어, 2025년 10월에는 미국에 본사를 둔 체외진단제 기업인 QuidelOrtho Corporation은 ORTHO VISION 플랫폼에서 겔 기반 직접 항글로불린 시험을 실시하는 MTS DAT Card에 대해 미국 식품의약국(FDA)의 승인을 받았습니다. 이 제품은 별도의 마이크로튜브 내의 겔 매트릭스에 항-IgG 및 항-C3d 단일특이성 시약을 함유하는 즉시 사용할 수 있는 카드가 특징입니다. 이 설계를 통해 IgG와 보체 감작을 명확하고 객관적으로 동시에 감별할 수 있어 면역 개재성 용혈성 빈혈과 태아 및 신생아 용혈성 질환의 조사를 효율화합니다. 적혈구와 결합한 면역글로불린 G 또는 보체를 검출하여 용혈 조사를 지원하고 수혈의 안전성을 높이는 것이 주요 목적입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장의 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 전략

제36장 부록

CSM
영문 목차

영문목차

A direct coombs test (DCT) antibody is an antibody that targets the dopachrome tautomerase (DCT) protein, also known as tyrosinase related protein 2 (TRP 2). This protein plays an important role in melanin biosynthesis and is commonly used as a marker for melanocyte differentiation and melanoma research. It is widely used to detect, measure, and study DCT expression in biological samples.

The main types of direct coombs test (DCT) antibody include monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and bispecific antibodies. Monoclonal antibodies are laboratory produced molecules created to bind specifically to antigens on red blood cells, allowing accurate detection of immune mediated hemolysis during diagnostic testing. The various sources include human, mouse, rabbit, other mammals, and recombinant sources and are used across applications such as cancer treatment, autoimmune diseases, infectious diseases, transplant rejection, and other related uses. The key end users include pharmaceutical companies, biotechnology firms, contract research organizations (CROs), academic and research institutes, and diagnostic laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The direct coombs test (DCT) antibody market research report is one of a series of new reports from The Business Research Company that provides direct coombs test (DCT) antibody market statistics, including direct coombs test (DCT) antibody industry global market size, regional shares, competitors with a direct coombs test (DCT) antibody market share, detailed direct coombs test (DCT) antibody market segments, market trends and opportunities, and any further data you may need to thrive in the direct coombs test (DCT) antibody industry. This direct coombs test (DCT) antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The direct coombs test (DCT) antibody market size has grown rapidly in recent years. It will grow from $5.87 billion in 2024 to $6.55 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to rising prevalence of hemolytic disease of the newborn, increasing autoimmune hemolytic anemia diagnoses, growing blood transfusion procedures, expanding hospital blood bank capacity, and rising antenatal screening programs.

The direct coombs test (DCT) antibody market size is expected to see rapid growth in the next few years. It will grow to $10.06 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to a growing geriatric population, rising oncology and hematology treatment volumes, expanding private diagnostic laboratory networks, growing demand for universal blood typing and cross matching, and increasing screening for hemolytic transfusion reactions. Major trends in the forecast period include integration of polymerase chain reaction based blood group genotyping with serology workflows, artificial intelligence assisted quality control and lot release analytics, Internet of Things enabled cold chain monitoring and traceability, adoption of cloud based laboratory information management systems, and advances in lyophilization and stabilizer chemistry for extended shelf life.

The rising demand for personalized medicine is expected to propel the growth of the direct coombs test DCT antibody market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable the precise identification of genetic variations and tailored treatments for individuals. Direct coombs test DCT antibody supports personalized medicine by enabling precise detection of antibodies or complement bound to red blood cells. It helps identify immune mediated hemolytic conditions, allowing clinicians to tailor treatments based on a patient's specific immune profile, improving diagnostic accuracy and therapeutic outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition PMC, a US based nonprofit organization, the United States Food and Drug Administration approved twenty six new personalized medicines in 2023, a significant increase from the twelve approved in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the direct coombs test DCT antibody market.

Major companies operating in the direct coombs test DCT antibody market are focusing on developing technologically advanced solutions such as gel based immunoassays to ensure reliability, enhance laboratory workflow, and maintain high standards in pre transfusion testing. Gel based immunoassays refer to a type of laboratory test in which antibodies and antigens interact within a gel matrix, allowing for visual detection of reactions such as agglutination. For instance, in October 2025, QuidelOrtho Corporation, a US based in vitro diagnostics company, received Food and Drug Administration clearance for MTS DAT Card for gel based direct antiglobulin testing on the ORTHO VISION platform. It features a ready to use card containing anti IgG and anti C3d monospecific reagents in the gel matrix of separate microtubes. This design allows for clear, objective, and simultaneous differentiation between IgG and complement sensitization, streamlining the investigation of immune mediated hemolytic anemias and hemolytic disease of the fetus and newborn. Its core purpose is to detect immunoglobulin G or complement bound to red blood cells, supporting hemolysis investigation and enhancing transfusion safety.

In March 2023, Werfen Life Sciences SA, a Spain based in vitro diagnostics company, acquired Immucor Inc. for approximately two point zero billion dollars. With this acquisition, Werfen aims to strengthen its leadership in transfusion medicine by integrating Immucor's immunohematology portfolio, enhancing automation, expanding global reach, and improving patient safety in hemolysis detection and transfusion management. Immucor Inc. is a US based company specializing in direct coombs test DCT antibody and immunohematology diagnostics.

Major companies operating in the direct coombs test (dct) antibody market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bio-Rad Laboratories Inc., Fortress Diagnostics Limited, Lab-Care Diagnostics (India) Pvt. Ltd., SIFIN Diagnostics GmbH, Hemo Bioscience Inc., Rapid Labs Ltd, AnaMol Laboratories Pvt. Ltd., Jiangyin Libo Biotechnology Co. Ltd., MicroSidd India Pvt. Ltd., Atlas Medical GmbH, Lorne Laboratories Ltd, Sanquin Reagents B.V., BAG Diagnostics GmbH, CE-Immundiagnostika GmbH, Biolab Diagnostics (India) Pvt. Ltd., Singapore Biosciences Pte. Ltd.

North America was the largest region in the direct coombs test (DCT) antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in direct coombs test (DCT) antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the direct coombs test (DCT) antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The direct coombs test (DCT) antibody consists of sales of primary antibodies, secondary antibodies, antibody kits, assay reagents, western blot reagents, enzyme-linked immunosorbent assay (ELISA) kits, immunohistochemistry kits, ready-to-use detection kit, anti- direct coombs test (DCT) (TRP-2), and rabbit monoclonal primary antibody. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Direct Coombs Test (DCT) Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on direct coombs test (dct) antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for direct coombs test (dct) antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The direct coombs test (dct) antibody market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Direct Coombs Test (DCT) Antibody Market Characteristics

3. Direct Coombs Test (DCT) Antibody Market Trends And Strategies

4. Direct Coombs Test (DCT) Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Direct Coombs Test (DCT) Antibody Growth Analysis And Strategic Analysis Framework

6. Direct Coombs Test (DCT) Antibody Market Segmentation

7. Direct Coombs Test (DCT) Antibody Market Regional And Country Analysis

8. Asia-Pacific Direct Coombs Test (DCT) Antibody Market

9. China Direct Coombs Test (DCT) Antibody Market

10. India Direct Coombs Test (DCT) Antibody Market

11. Japan Direct Coombs Test (DCT) Antibody Market

12. Australia Direct Coombs Test (DCT) Antibody Market

13. Indonesia Direct Coombs Test (DCT) Antibody Market

14. South Korea Direct Coombs Test (DCT) Antibody Market

15. Western Europe Direct Coombs Test (DCT) Antibody Market

16. UK Direct Coombs Test (DCT) Antibody Market

17. Germany Direct Coombs Test (DCT) Antibody Market

18. France Direct Coombs Test (DCT) Antibody Market

19. Italy Direct Coombs Test (DCT) Antibody Market

20. Spain Direct Coombs Test (DCT) Antibody Market

21. Eastern Europe Direct Coombs Test (DCT) Antibody Market

22. Russia Direct Coombs Test (DCT) Antibody Market

23. North America Direct Coombs Test (DCT) Antibody Market

24. USA Direct Coombs Test (DCT) Antibody Market

25. Canada Direct Coombs Test (DCT) Antibody Market

26. South America Direct Coombs Test (DCT) Antibody Market

27. Brazil Direct Coombs Test (DCT) Antibody Market

28. Middle East Direct Coombs Test (DCT) Antibody Market

29. Africa Direct Coombs Test (DCT) Antibody Market

30. Direct Coombs Test (DCT) Antibody Market Competitive Landscape And Company Profiles

31. Direct Coombs Test (DCT) Antibody Market Other Major And Innovative Companies

32. Global Direct Coombs Test (DCT) Antibody Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Direct Coombs Test (DCT) Antibody Market

34. Recent Developments In The Direct Coombs Test (DCT) Antibody Market

35. Direct Coombs Test (DCT) Antibody Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기